- Home
- VRCA
as 05-31-2024 4:00pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 363.1M | IPO Year: | 2018 |
| Target Price: | $13.50 | AVG Volume (30 days): | 188.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $11.41 | Next Earning Date: | 05-13-2024 |
| Revenue: | $8,913,000 | Revenue Growth: | 3.18% |
| Revenue Growth (this year): | 394.65% | Revenue Growth (next year): | 167.23% |
Stock Insider Trading Activity of Verrica Pharmaceuticals Inc. (VRCA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 27 '23 | Buy | $7.20 | 79,726 | $574,027.20 | 6,857,292 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 27 '23 | Buy | $7.08 | 126,116 | $892,901.28 | 6,983,408 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 27 '23 | Buy | $7.24 | 115,774 | $838,203.76 | 7,099,182 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 21 '23 | Buy | $6.17 | 200,000 | $1,234,000.00 | 6,472,914 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 21 '23 | Buy | $6.67 | 250,000 | $1,667,500.00 | 6,722,914 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | VRCA | 10% Owner | Dec 21 '23 | Buy | $6.49 | 54,652 | $354,691.48 | 6,777,566 | SEC Form 4 |
| Hayes Christopher G. | VRCA | Chief Legal Officer | Nov 14 '23 | Sell | $2.97 | 11,558 | $34,327.26 | 123,226 | SEC Form 4 |
| Hayes Christopher G. | VRCA | Chief Legal Officer | Nov 14 '23 | Sell | $2.93 | 22,141 | $64,873.13 | 134,784 | SEC Form 4 |
| Bonaccorso Joe | VRCA | Chief Commercial Officer | Nov 14 '23 | Sell | $2.93 | 21,580 | $63,229.40 | 103,658 | SEC Form 4 |
| Bonaccorso Joe | VRCA | Chief Commercial Officer | Nov 14 '23 | Sell | $2.97 | 11,266 | $33,460.02 | 92,392 | SEC Form 4 |
| Kohler Terry | VRCA | Chief Financial Officer | Nov 14 '23 | Sell | $2.93 | 18,452 | $54,064.36 | 44,048 | SEC Form 4 |
| Kohler Terry | VRCA | Chief Financial Officer | Nov 14 '23 | Sell | $2.97 | 9,632 | $28,607.04 | 34,416 | SEC Form 4 |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Simply Wall St.
3 days ago
High Insider Ownership Growth Companies On US Exchange May 2024
MT Newswires
18 days ago
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth
GlobeNewswire
18 days ago
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
MT Newswires
19 days ago
HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating
MT Newswires
19 days ago
Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating
GuruFocus.com
19 days ago
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com
20 days ago
Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.